Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1925-1933

  Schwegler, Christian ^a   Dorn Beineke, Alexandra ^b   Nittka, Stefanie ^b   Stocking, Carol ^c   Neumaier, Michael ^b,d  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6G6.C4; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS REACTION; DRUG ACTIVITY; FEMALE; FLOW CYTOMETRY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOEMBRYONIC ANTIGEN; CELL PROLIFERATION; CELLS, CULTURED; COLON; COLONIC NEOPLASMS; EPITOPES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM CIRCULATING CELLS; RECOMBINANT FUSION PROTEINS;

EID: 16444369044     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3591     Document Type: Article

References (47)

1. Hammarstrom S, Baranov V. Is there a role for CEA in innate immunity in the colon? Trends Microbiol 2001;9:119-25.
2. Abe H, Kuroki M, Tachibana K, et al. Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res 2002;22:1575-80.
3. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002;94:1373-81.
4. Baral R, Sherrat A, Das R, et al. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu. Int J Cancer 2001;92:88-95.
5. Schlebusch H, Wagner U, Grunn U, et al. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 1995;14:167-74.
6. Spendlove L, Li L, Potter V, et al. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol 2000;30:2944-53.
7. Tripathi PK, Qin H, Deng S, et al. Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Mol Immunol 1998;35:853-63.
8. Uemura H, Beniers AJ, Okajima E, et al. Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity. Int J Cancer 1994;58:555-61.
9. Alfonso M, Diaz A, Hernandez AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168:2523-9.
10. Foon KA, Oseroff AR, Vaickus L, et al. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1995;1:1285-94.
11. Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999;17:2889-5.
12. Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000;18:376-84.
13. Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10:1580-7.
14. Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 7:1112-1115, 2001. Clin Cancer Res 2001;7:1154-62.
15. Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 7:1112-1115, 2001. Clin Cancer Res 2001;7:1154-62.
16. Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 7:1112-1115, 2001. Clin Cancer Res 2001;7:1154-62.
17. Gaida F-J, Fenger U, Wagener C, et al. A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen. Int J Cancer 1992;51:459-65.
18. Gaida FJ, Pieper D, Roder UW, et al. Molecular characterization of a cloned idiotypic cascade containing a network antigenic determinant specific for the human carcinoembryonic antigen. J Biol Chem 1993;268:14138-45.
19. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001;248:91-101.
20. Reinartz S, Hombach A, Kohler S, et al. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res 2003;63:3234-40.
21. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-8.
22. Tripathi PK, Qin H, Bhattacharya-Chatterjee M, et al. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma 1999;18:193-202.
23. Xu X, Clarke P, Szalai G, et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000;60:4475-84.
24. Fischer HG, Frosch S, Reske K, et al. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988;141:3882-8.
25. Coleman DL, Chodakewitz JA, Bartiss AH, et al. Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood 1988;72:573-8.
26. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
27. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993;329:1-9.
28. Batova A, Kamps A, Gillies SD, et al. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res 1999;5:4259-63.
29. Neumaier M, Shively L, Chen FS, et al. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res 1990;50:2128-34.
30. Dexter TM, Garland J, Scott D, et al. Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 1980;152:1036-47.
31. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169-76.
32. Kensil CR, Patel U, Lennick M, et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991;146:431-7.
33. Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J 1996;10:49-56.
34. r 160,000 antigen of the CD66 cluster to a mRNA encoded by the biliary glycoprotein (BGP) gene, a member of the carcinoembryonic antigen (CEA) gene family. J Immunol 1993;150:4978-84.
35. Birebent B, Mitchell E, Akis N, et al. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 2003;21:1601-12.
36. Gruber R, van Haarlem LJ, Warnaar SO, et al. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 2000;60:1921-6.
37. Staib L, Birebent B, Somasundaram R, et al. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001;92:79-87.
38. Hoffmann P, Mueller N, Shively JE, et al. Fusion proteins of B7.1 and a carcinoembryonic antigen (CEA)-specific antibody fragment opsonize CEA-expressing tumor cells and coactivate T-cell immunity. Int J Cancer 2001;92:725-32.
39. Holliger P, Manzke O, Span M, et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 1999;59:2909-16.
40. Saha A, Chatterjee SK, Foon KA, et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004;64:4995-5003.
41. Hjelm Skog A, Ragnhammar P, Fagerberg J, et al. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony- stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol Immunother 1999;48:463-70.
42. Coelho M, Gauthier P, Pugniere M, et al. Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br J Cancer 2004;90:2032-41.
43. Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83.
44. Kass E, Panicali DL, Mazzara G, et al. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14.
45. Hodge JW, Grosenbach DW, Aarts WM, et al. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003;9:1837-49.
46. Zeytin HE, Patel AC, Rogers CJ, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 2004;64:3668-78.
47. Mizobata S, Tompkins K, Simpson JF, et al. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 2000;49:285-95.